Onkologie. 2017:11(5):228-230 | DOI: 10.36290/xon.2017.043

Care for BRCA1 and BRCA2 gene carriers from the gynecologist's point of view

Helena Kolářová
Klinika operační onkologie, Oddělení gynekologické onkologie, Masarykův onkologický ústav
a Lékařská fakulta Masarykovy univerzity Brno

The article deals with the issue of care for BRCA1 and BRCA2 gene carriers, it means women with hereditary disposition for breastand ovarian cancer, from the gynecologist's point of view, and summarizes the recommendations for the dispensarization andthe implementation of preventive surgical procedures – adnexectomy with hysterectomy. The importance of caring for BRCA1,2gene mutations is emphasized with regard to the severity of ovarian carcinoma. The article draws attention to the fact that, accordingto the NCCN-modified indication criteria from 2015 and approved by the Society of Medical Genetics and Genomics ofthe ČLS JEP, genetic testing for all women with ovarian carcinoma without age and histological limitation is indicated to providedata for targeted cancer treatment using the inhibitors of PARP-poly (ADP-ribose) polymerase and to increase the detection ofmutations in affected families.

Keywords: hereditary breast and ovarian cancer syndrome, mutation of BRCA1 gene, mutation of BRCA2 gene

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolářová H. Care for BRCA1 and BRCA2 gene carriers from the gynecologist's point of view. Onkologie. 2017;11(5):228-230. doi: 10.36290/xon.2017.043.
Download citation

References

  1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266(5182): 66-71. Go to original source... Go to PubMed...
  2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559): 789-792. Go to original source... Go to PubMed...
  3. Zikán M. Hereditární syndromy. In:Cibula D. A kol. Onkogynekologie. Grada. Praha 2009: 69-82.
  4. Foretová L, Svoboda M, Slabý O. Molekulární genetika v onkologii. Mladá Fronta. Praha 2014: 184 s.
  5. Evans DG, Shenton A, Woodward E, et al. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008; 8: 155. doi: 10.1186/1471-2407-8-155. Go to original source... Go to PubMed...
  6. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62(3): 676-689. Go to original source... Go to PubMed...
  7. Thompson D, Easton DF. Breast Cancer Linkage Con-sortium. Cancer incidence in BRCA1 mutation carriers. J Nat Cancer Inst 2002; 94(18): 1358-1365. Go to original source...
  8. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94(18): 1365-1372. Go to original source...
  9. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. J Hum Genet 2003; 72(5): 1117-1130. Go to original source... Go to PubMed...
  10. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 Penetrance. J Clin Oncol 2007; 25(11): 1329-1333. Go to original source... Go to PubMed...
  11. NCCN Guidelines version 2.2015 (online). Hereditary breast and/or ovarian cancer syndrome. National Comprehensive Cancer Network. Availabla from: http://www.nccn.org.professionals/physician_gls/f_guidelines.asp
  12. Song H, Cicek MS, Dicks E et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet 2014; 23(17): 4703-4709. Go to original source... Go to PubMed...
  13. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005; 23(1): 127-132. Go to original source... Go to PubMed...
  14. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26(8): 1331-1337. Go to original source... Go to PubMed...
  15. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346(21): 1616-1622. Go to original source...
  16. Falconer H, Yin L, Gronberg H, et al. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Nat Cancer Inst 2015; 107(2): pii: dju410. doi:10.1093/jnci/dju410. Go to original source...
  17. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-236. Go to original source...
  18. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer - is it safe), a randomized comparison: trial stopped. Lancet 2004; 363(9407): 453-455. Go to original source... Go to PubMed...
  19. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomized, non-inferiority trial. Lancet Oncol 2009; 10(2): 135-146. Go to original source... Go to PubMed...
  20. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004; 22(7): 1315-1327. Go to original source... Go to PubMed...
  21. Skates SJ, Mai P, Horick NK, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res 2011; 4(9): 1401-1408. Go to original source... Go to PubMed...
  22. Zikán M. Gynekologická prevence a gynekologické aspekty péče u nosiček genů BRCA1 a BRCA2. Klin Onkol 2016; 26(Suppl.1): S22-30. Go to original source... Go to PubMed...
  23. Antoniou AC, Rookus M, Andrieu N, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009; 18(2): 601-610. doi: 10.1158/1055-9965.EPI-08-0546. Go to original source... Go to PubMed...
  24. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8(1): 26-34. Go to original source... Go to PubMed...
  25. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345(4): 235-240. Go to original source... Go to PubMed...
  26. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339(7): 424-428. Go to original source...
  27. Seznam onkologických pracovišť a onkologů zajišťujících prevenci pro osoby (i zdravé) s dědičným rizikem nádorů. Klin Onkol 2016; 29(Suppl 1): S6-S8.




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.